Do BPC-157 or TB-500 heal tendons and soft tissue?
They are plausible healing candidates, but the size of the benefit in people is still unknown. Animal studies and real-world interest have moved BPC-157 and TB-500 into serious discussion. The next step is controlled human data, including a Phase 2 BPC-157 hamstring trial that is now recruiting.
- BPC-157
- A randomized Phase 2 hamstring study is recruiting 120 adults.
- TB-500
- FDA found no medical-literature study in which TB-500 was administered to humans.
- U.S. status
- No approved pain indication. An FDA advisory panel recommended both for the 503A compounding list in July 2026.
- Sport status
- WADA prohibits BPC-157 and TB-500 at all times for covered athletes.
Why the science is interesting
Animal and laboratory studies report changes in blood vessels, inflammation, collagen organization, and tissue repair. Those are useful biological signals. Human trials are needed to learn whether the effects are large enough to improve walking, strength, pain, or recovery time in people.
BPC-157: a human trial is underway
A recruiting Phase 2 study plans to compare BPC-157 with placebo in 120 adults with acute hamstring strains while both groups receive standard rehabilitation. Its outcomes include return to sport, MRI injury volume, pain, strength, and function. This is exactly the kind of study needed to turn a promising signal into a measurable estimate of benefit.
TB-500: human results are still needed
FDA’s July 2026 review found no published human administration study for the TB-500 fragment. FDA also distinguished TB-500 from full thymosin beta-4, so findings about one should not automatically be assigned to the other.
The July 2026 FDA advisory vote
The FDA’s Pharmacy Compounding Advisory Committee recommended placing BPC-157 and TB-500 on the 503A Bulks List. This was a meaningful step toward allowing licensed pharmacies to compound them by prescription. It did not create an FDA-approved pain indication, and final FDA action is still required.
Why the WADA bans matter—and what they do not prove
WADA’s 2026 Prohibited List names BPC-157 under S0, “Non-Approved Substances,” and lists thymosin-β4 and derivatives such as TB-500 under S2 growth factors and growth-factor modulators. Both are prohibited at all times for athletes governed by the anti-doping code.
This is a real regulatory signal: anti-doping authorities consider the substances relevant to performance and fair competition. It is not proof of medical effectiveness. WADA’s standard includes substances with the potential to enhance performance or pose risk; it does not require a completed pain or tendon-healing trial. A sports ban cannot substitute for evidence that patients heal faster or function better.
What should be identified first
Tendon pain can come from an acute tear, chronic tendinopathy, referred nerve pain, inflammatory disease, or a load problem that will remain after any injection. Imaging can be useful in selected cases, but an image finding also is not automatically the cause of pain. The useful question is what tissue is involved, why it is failing, and what outcome is being measured.
Our verdict: There is enough biological and real-world interest to justify serious human research. The honest unknown is not whether the ideas are interesting—it is how often they help, by how much, and with what risks.
Primary sources
- FDA briefing document on BPC-157 (July 2026)
- Registered BPC-157 hamstring-injury study
- FDA briefing document on TB-500 (July 2026)
- FDA advisory committee meeting and materials (July 23–24, 2026)
- Associated Press report on the advisory committee vote (July 23, 2026)
- WADA 2026 Prohibited List — current anti-doping status for BPC-157 and TB-500
Last reviewed August 11, 2026. Compounding-list status and FDA drug approval are different regulatory paths.